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Abstract
Introduction: Breast cancer is a heterogeneous disease and may be characterized on the basis of whether
estrogen receptors (ER) are expressed in the tumour cells. ER status of breast cancer is important clinically, and is
used both as a prognostic indicator and treatment predictor. In this study, we focused on identifying genetic
markers associated with ER-negative breast cancer risk.
Methods: We conducted a genome-wide association analysis of 285,984 single nucleotide polymorphisms (SNPs)
genotyped in 617 ER-negative breast cancer cases and 4,583 controls. We also conducted a genome-wide pathway
analysis on the discovery dataset using permutation-based tests on pre-defined pathways. The extent of shared
polygenic variation between ER-negative and ER-positive breast cancers was assessed by relating risk scores,
derived using ER-positive breast cancer samples, to disease state in independent, ER-negative breast cancer cases.
Results: Association with ER-negative breast cancer was not validated for any of the five most strongly associated
SNPs followed up in independent studies (1,011 ER-negative breast cancer cases, 7,604 controls). However, an
excess of small P-values for SNPs with known regulatory functions in cancer-related pathways was found (global P
= 0.052). We found no evidence to suggest that ER-negative breast cancer shares a polygenic basis to disease with
ER-positive breast cancer.
Conclusions: ER-negative breast cancer is a distinct breast cancer subtype that merits independent analyses. Given
the clinical importance of this phenotype and the likelihood that genetic effect sizes are small, greater sample sizes
and further studies are required to understand the etiology of ER-negative breast cancers.
Introduction
Breast cancer is a heterogeneous disease and can be
characterized on the basis of estrogen receptor (ER)
expression in the tumour cells. The two breast cancer
subtypes (ER-positive and ER-negative) are generally
considered as biologically distinct diseases and have
been associated with remarkably different gene expres-
sion profiles [1,2]. ER status is important clinically, and
is used both as a prognostic indicator and treatment
predictor since it determines if a patient may benefit
from anti-estrogen therapy. Approximately one-third of
all breast cancers are ER-negative, and cancers of this
ER subtype are highly age-dependent and generally have
a more aggressive clinical course than hormone recep-
tor-positive disease.
Estimates show that close to a third of the total risk of
breast cancer may be attributed to heritable factors [3].
Several large-scale genome-wide single nucleotide poly-
morphism (SNP) association studies (GWAS) have iden-
tified multiple susceptibility loci for breast cancer [4-11],
but it is estimated that the currently known common
risk variants identified by this approach explains only
5.8% of the proportion of familial risk of breast cancer.
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based approaches have also emerged in the recent
GWAS literature [12-20]. These novel methods have
been developed to mine modest association signals from
genome-wide SNP data using prior knowledge on biolo-
gically pathways and networks, and have the potential to
complement traditional agnostic SNP approaches to
provide fertile grounds for follow-up studies of both a
genetic and molecular nature. Subtypes of breast cancer,
to our knowledge, have not been studied using a path-
way-based approach.
Although many of the SNPs identified for breast can-
cer through GWAS scans have been found to be more
strongly associated with ER-positive disease than ER-
negative disease [21,22], there is no quantitative assess-
ment on whether breast cancers of the two different ER
subtypes share a polygenic component. In this study, we
performed a genome-wide association scan on 617 ER-
negative cases and 4,583 controls, the first of its kind,
and examined 285,984 SNPs for common variants and
biological pathways associated with this unique subtype
of breast cancer. We also searched for evidence that ER-
negative breast cancer is distinct from ER-positive breast
cancer by assessing the amount of shared polygenic var-
iation between the two breast cancer subtypes.
Materials and methods
Full methods accompany this paper in Additional file 1.
Study populations used in the discovery stage
Table 1 summarizes the demographics of cases and con-
trols used in this study. The discovery stage consists of
cases and controls from Finland and Sweden. The vali-
dation stage consists of breast cancer cases from two
further studies: the Study of Epidemiology and Risk fac-
tors in Cancer Heredity (SEARCH) and Rotterdam
Breast Cancer Study (RBCS) (1,011 ER-negative cases,
7,604 controls), both previously described in Lesueur
et al. [23]. Informed consent was obtained from all sub-
jects. For all populations, blood samples were obtained
from individuals according to protocols and informed-
consent procedures approved by institutional review
boards.
Briefly, the Swedish sample set included subjects who
were drawn from a parent population-based case control
study of postmenopausal breast cancer which has been
described elsewhere [24,25]. Case subjects were women
born in Sweden who were 50 to 74 years of age at diag-
nosis and diagnosed with breast cancer between October
1993 and March 1995. A total of 803 individuals diag-
nosed with invasive breast cancer and with available
blood samples were selected for GWAS genotyping in
an independent GWAS looking at overall breast cancer
risk [26]. Of these women, 153 individuals were diag-
nosed with the ER-negative disease and were included
in the present study. In addition, a total of 1,414 Swed-
ish controls were included from the parent study and an
additional Epidemiological Investigation of Rheumatoid
Arthritis (EIRA) study [27].
The Finnish breast cancer study population consists of
two series of unselected breast cancer patients and addi-
tional familial cases ascertained at the Helsinki Univer-
sity Central Hospital. The first series of patients was
collected in 1997 to 1998 and 2000 and covers 79% of
all consecutive, newly diagnosed cases during the collec-
tion periods [28,29]. The second series, containing
newly diagnosed patients, was collected in 2001 to 2004
and covers 87% of all such patients treated at the hospi-
tal during the collection period [30]. The collection of
additional familial cases has been described previously
[31]. We genotyped a total of 782 breast cancer cases in
an independent GWAS for overall breast cancer risk
Table 1 Summary of samples and genotyping platforms used in the discovery and validation stages
Stage Study Type No. of samples after quality
control
Genotyping platform
Discovery Swedish ER-negative cases 153 HumanHap300 supplemented by
HumanHap240S
Controls 764 HumanHap550
Additional controls from EIRA
study
650 HumanHap300
Finnish ER-negative cases 226 HumanHap550
ER-negative cases 238 Quad610 (v1)
Controls 3169 HumanHap370Duo
Validation SEARCH and
RBCS
ER-negative cases 1011 Taqman
Controls 7604 Taqman
ER, estrogen receptor; RBCS, Rotterdam Breast Cancer Study; SEARCH, Study of Epidemiology and Risk factors in Cancer Heredity.
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present study. An additional 238 Finnish ER-negative
cases were also genotyped for this study, using a differ-
ent platform. Of these 464 women with ER-negative
breast cancer, 207 were sporadic and 257 were familial
breast cancer cases. Population control data were
obtained from the Finnish Genome Centre on 3,169
healthy population controls described in [32-35].
SEARCH is a population-based case-control study
comprising 7,093 cases identified through the East
Anglian Cancer Registry: prevalent cases diagnosed age
<55 from 1991 to 1996 and alive when the study started
in 1996, and incident cases diagnosed <70 diagnosed
after 1996. Controls (N = 8,096) were selected from the
EPIC-Norfolk cohort study, a population-based cohort
study of diet and health based in the same geographical
region as SEARCH, together with additional SEARCH
controls recruited through general practices in East
Anglian region.
RBCS is a hospital-based case-control study compris-
ing 799 cases characterized as familial breast cancer
patients selected from the Rotterdam Family Cancer
Clinic at the Erasmus Medical Center, of which 141 are
ER-negative. Controls (N = 801) were spouses or muta-
tion-negative siblings of heterozygous Cystic Fibrosis
mutation carriers selected from the Department of Clin-
ical Genetics at the Erasmus Medical Center. Both cases
and controls were recruited between 1994 and 2006.
Genotyping and quality control filters
Genotyping for all samples was performed according to
the Illumina Infinium 2 assay manual (Illumina, San
Diego, CA, USA), as described previously [36]. The
genotyping platforms used for this study are listed in
Table 1. Apart from the 3,170 Finnish controls which
were genotyped on the HumanHap370Duo assay as
described previously [32,34], genotyping for all other
Finnish and Swedish samples was performed at the
Genome Institute of Singapore.
Each dataset was filtered to remove individuals with
>10% missing genotypes, and SNPs with >10% missing
data, or minor allele frequency (MAF) <0.03, or not in
Hardy-Weinberg equilibrium (HWE) (P <0 . 0 5 / n u m b e r
of SNPs after quality control) and individual samples
with evidence of possible DNA contamination, common
ancestry or cryptic family relationships. Quality control
was carried out using the software Plink [37]. To
account for population outliers and correct for differen-
tial ancestry between cases and controls that may exist
in the dataset after familial outlier removal, a principal
component (PC) analysis was conducted using the
EIGENSTRAT software (Broad Institute, Boston, MA,
USA) [38].
A total of 617 ER-negative cases and 4,583 controls
passed the quality control for samples. The 285,984
SNPs that passed quality control filters in all sample
sets were merged into a single file for analysis.
The five most strongly associated SNPs in the com-
bined analysis, which had effects in the same direction
for both studies in the discovery stage (Swedish and Fin-
nish) were forwarded for validation in SEARCH and
RBCS. Genotyping in SEARCH and RBCS was per-
formed by 5’exonuclease assay (Taqman) using the ABI
Prism 7900HT sequence detection system (Applied Bio-
systems, Foster City, CA, USA) according to the manu-
facturer’s instructions.
A l lS N Pc h r o m o s o m a lp o s i t i o n sw e r eb a s e do nN C B I
Build 36.
Statistical analysis
Figure 1 gives a broad overview of the analytical strategy
for the single marker association analysis and pathway
analysis.
Single marker association analysis
Logistic regression models with genotype coded 0, 1, 2
and treated as a continuous covariate (one at a time),
were fitted for each SNP that passed quality control. An
additive genetic effect on the logit scale was assumed to
characterize the associations. Separate analyses were
performed for the Swedish and Finnish datasets as well
as a combined analysis.
In the combined analysis, the final model included as
covariates the SNP genotype, an indicator variable speci-
fying country (Sweden and Finland), and interaction
effects of Eigen values of PCs × country specified in
such a way that country-specific PCs were implemented
for the relevant subjects. Quantile-quantile plots were
used to check for systematic genotyping error or bias
due to unaccounted underlying population substructure.
Manhattan plots were generated to summarize the -log
transformed P-values of all SNPs examined.
Pathway analysis using discovery set (Swedish and Finnish
samples)
Pathway analysis of the discovery GWAS dataset was
conducted using the SNP ratio test (SRT) SRT was used
to investigate the associations with breast cancer for 212
pathways and their genes (approximately 4,700) taken
from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database (05/12/08) [39].
To evaluate the association between regulatory SNPs-
defined pathways and ER-negative breast cancer, we
used the downloadable database from mRNA by SNP
Browser [40] to map SNPs, which are significantly asso-
ciated with gene expression on a genome-wide level
(LOD >6), to genes. In total, 7,698 SNPs were mapped
to 3,740 probes with a LOD score >6. These 3,740
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these, 554 genes, regulated by 1,720 SNPs, were anno-
tated as belonging to one or several of the 182 KEGG
pathways.
Among five regulatory SNP-defined pathways found to
be significantly associated with ER-negative breast can-
cer, four belonged to the pathway class “cancer”.T o
evaluate if the abundance of small P-values from regula-
tory SNPs involved in cancer-related pathways was sta-
tistically significant as a whole, we also assessed the
departure of the distribution of the trend test statistics
from the null distribution, assuming that none of the
SNPs was associated with ER-negative breast cancer as
an outcome. For this purpose, we performed the
“admixture maximum likelihood” test described by
Tyrer et al. [41] to obtain a global P-value for 165
unique SNPs from 15 cancer-related pathways (hsa052*)
curated in the KEGG database.
Analysis of shared polygenic variation between ER-negative
and ER-positive breast cancer subtypes
We assessed the polygenic component of breast cancer
risk using a procedure for creating sample scores which
has been described elsewhere [42]. Briefly, ER-positive
breast cancer cases and healthy controls from either the
Finnish or Swedish study were used as a “training set”
to derive a list of SNPs used for scoring in two “target
Figure 1 Schematic diagram of analytical strategies for agnostic single marker association analysis and pathway analysis.
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and healthy controls or ER-negative breast cancer cases
and healthy controls in the other population. Figure 2
gives a broad overview of the analytical strategy for
assessing common polygenic variation.
The polygenic score for each individual was calculated
by summing the number of score alleles weighed by the
log of their odds ratio from the training sample, across
all SNPs included in the score. SNPs were included in
the score if they achieved a P-value less than a particular
threshold in the training sample. The “—score” function
in Plink [37] was used to calculate scores. To capture
association signals with very small effects in the calcula-
tion of the polygenic component of the disease, we used
non-stringent significance thresholds (P < 0.01, P < 0.05,
P < 0.10, P < 0.20, P <0 . 3 0 ,P <0 . 4 0a n dP < 0.50).
Scores were calculated for the seven P-value thresholds.
The extent of shared polygenic variation between ER-
positive breast cancers in the training sample and ER-
positive and ER-negative breast cancers in the corre-
sponding target samples was assessed by fitting logistic
regression models to disease state, as a function of score,
in the target samples. Regression models, adjusted for the
number of non-missing genotypes, were fitted to assess
the differences in the extent of shared polygenic variation
(scores) between the ER-positive and ER-negative target
samples in case-only analyses.
PLINK (v1.06) [37], SNP Ratio Test [19], R (v2.8.0)
[43], Quanto [44], AML [41], Qlikview (v8.5) [45], Hap-
loView [46] and LocusZoom [47] were used for data
management, quality control, statistical analyses, and
graphics. All reported tests are two-sided.
Results
In this study, we tested the association of 285,984 loci
with ER-negative breast cancer in two independent
populations consisting of a total of 617 cases and 4,583
controls. It appears that the overall population substruc-
ture was adequately accounted for, since a systematic
deviation from the expected distribution was not
observed in the quantile-quantile plot (Supplementary
Figures 2, 3 and 4 in Additional file 2). Quantile-quan-
tile plots generated from the analyses of individual data-
sets showed that there was no within-study systematic
error arising from the use of non-matched population
controls or genotyping at different facilities (Supplemen-
tary Figures 2 and 3 in Additional file 2). Genotype clus-
ter plots were examined for SNPs with P <1 0
-5. Manual
reclustering was performed for six SNPs with poor gen-
otype cluster plots. SNPs rs4660646 and rs2462692 were
Figure 2 Summary of scoring procedure for assessment of common polygenic variation.
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reclustered. SNPs rs4549482, rs1984492, rs1389545 and
rs3748648 were not found to be strongly associated with
ER-negative breast cancer after reclustering (Table S1 in
Additional file 3).
Figure 3 shows a Manhattan plot summarizing the
-log-transformed P-values of 285,984 SNPs analyzed in
this study. In a combined analysis of individuals of
Swedish and Finnish backgrounds, the strongest asso-
ciation with ER-negative breast cancer below the
threshold for genome-wide significance was for a locus
marked by rs361147 on chromosome 4 (P trend = 3.13
×1 0
-13;O Rper allele = 0.60) (Table S2 in Additional file
3). This was the only SNP to achieve statistical signifi-
cance at the genome-wide level (a =5×1 0
-8). Overall,
no significant signal peak was identified in this study
(Figures 4, 5, 6, 7, 8).
Nevertheless, we selected five SNPs to be validated in
a combined dataset of two independent studies (Table
S2 in Additional file 3). SNPs rs7039994 and
rs12000794, located 106310 base pairs away from each
other on chromosome 9, were found to be in high LD
(r2 = 0.797; D’ = 0.952). The former was kept and vali-
dated in the SEARCH dataset as its associated P-value
was smaller and it was in closer proximity to coding
regions (downstream of INVS|TEX10). SNP rs3777218
was selected over rs11882068 due to a better regional
signal peak. Other SNPs selected for validation included
rs361147 as mentioned above, rs6993922, rs4726078
(within transcript of PRKAG2), and rs3777218 (within
transcript of RHOBTB3). Of the five SNPs forwarded for
validation, rs4726078 could not be designed and was
replaced by rs10952315 (r2 = 0.977 in Centre d’Etude
du Polymorphisme Humain (CEPH) from Utah (CEU)
HapMap samples). None of the SNPs was significantly
associated at the 5% level in the second stage. The smal-
lest P-value obtained was for the surrogate rs10952315
(OR 1.02; 95% CI: 0.93 to 1.13).
To analyze our GWAS data in a pathway context we
conducted a permutation-based analysis using the
KEGG database. Pathways defined by SNPs located
within transcript of genes that were found to be signifi-
cantly associated with ER-negative breast cancer after
1,000 phenotype permutations at a threshold of Pa =0 . 0 5
< 0.05 (uncorrected) were: pentose and glucuronate
interconversions (hsa00040) (P = 0.022), starch and
sucrose metabolism (hsa00500) (P = 0.042), and gap
junction (hsa04540) (P = 0.037) (Table 2).
In addition, we limited the analysis to pathway defini-
tions involving only known regulatory SNPs [48]. The
GWAS SNPs were first mapped to genes, and then sub-
sequently to KEGG pathways based on publicly available
Figure 3 Genome-wide P-values (-log10P) of the logistic regression analysis plotted against chromosomal position.
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Figure 4 Plot of regional association signals for rs361147 forwarded for validation.
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Page 7 of 17Figure 6 Plot of regional association signals for rs6993922 forwarded for validation.
Figure 7 Plot of regional association signals for rs4726078 forwarded for validation.
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Only genes with regulatory functions significant on a
genome-wide significant level were selected, resulting in
1,720 SNPs regulating members of 182 KEGG pathways
being used in our analysis. Pathways that were found to
be significant by SRT after 1,000 phenotype permuta-
tions at a threshold of Pa =0 . 0 5< 0.05 were: long-term
potentiation (hsa04720), glioma (hsa05214), non-small
cell lung cancer (hsa05223), pancreatic cancer
(hsa05212), and prostate cancer (hsa5215) (Table 3).
The focal adhesion pathway (hsa04510) was found to be
marginally significant (Pa = 0.05 = 0.052). Two pathways
each tagged by only a single SNP, glyoxylate and dicar-
boxylate metabolism (hsa00630) and glycosphingolipid
biosynthesis - ganglio series (hsa00604), were removed
from the evaluation of the final results.
Regulatory SNPs involved in pathways associated with
cancer (hsa052*) appeared to be overrepresented by
small P-values (Figure 9). To evaluate if the combined
effect of these signals was statistically significant as a
whole, we next carried out a global test of significance
for all unique SNPs in the cancer pathways. The AML
analysis performed using an algorithm developed by
Tyrer et al. [41], yielded P-values (a = 0.05) of 0.0028
(crude) and 0.052 (adjusted for population stratification).
Figure 10 shows the results of analyses aimed at asses-
sing the shared polygenic component between ER-posi-
tive and ER-negative breast cancer. Estimates of
variance explained in datasets indicate how important
the polygenic component of ER-positive disease is in
explaining the overall occurrence of ER-positive and ER-
negative diseases. The proportion of variance explained
for all categories of P-value cut-offs, with the exception
of P < 0.05 in the Swedish ER-positive target sample,
was higher in the ER-positive target datasets than the
ER-negative target datasets.
We test for association between polygenic score and
disease status (ER-positive vs controls/ER-negative vs
controls) in the target data, when seven groups of SNPs
with different P-values thresholds in the training sets
were considered (Figure 10a, b). Due possibly to limited
statistical power (Table S3 in Additional file 3), even at
the least stringent P-value threshold (P < 0.50), the ER-
positive and ER-negative breast cancer target case-con-
trol datasets failed to provide statistically significant evi-
dence of a polygenic component for ER-positive cancer,
or evidence of a polygenic component shared between
the two cancers, when training was based on the ER-
positive training case-control datasets (Figure 10a, b).
Nevertheless, when we relaxed the P-value cut-off in the
Figure 8 Plot of regional association signals for rs3777218 forwarded for validation.
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cancer target dataset showed borderline significance for
a shared polygenic component with ER-positive breast
cancer, based on the Finnish ER-positive training dataset
(Figure 10a, P = 0.066).
In a separate case-only analysis, we performed a sig-
nificance test for difference in scores between ER-posi-
tive and ER-negative breast cancer cases in the target
data. Significant results show that ER-positive and ER-
negative breast cancers are not identical diseases
(genetically at polygenic level) (Figures 10c, d). The dif-
ference in scores between ER-positive and ER-negative
samples was found to be statistically significant for all
categories of P-value cut-offs in the Finnish target case-
only samples, with the exception of the most associated
SNPs (Figure 10d).
Discussion
Little is known about the genetic predisposition to
estrogen receptor-negative breast cancer. This subtype is
characterized by lower age of onset, a more aggressive
disease and low or no response to selective estrogen
receptor modulators or aromatase inhibitors. We have
examined our GWAS data on two different levels: single
marker and pathway. We also provided evidence that
breast cancer is a heterogeneous disease with a poly-
genic nature, with significant differences between the
polygenic component between ER-positive and ER-
Table 2 Top ranking pathways of genome-wide pathway analysis results using SNP ratio test (P < 0.1)
KEGG ID Pathway name
Class
No. of SNPs
P < 0.05
No. of SNPs in pathway Number of
significantly
associated SNPs with
P
E-05 E-04 E-03 E-02 P
00040 Pentose and glucuronate interconversions
Metabolism; Carbohydrate Metabolism
11 63 0 1 2 8 0.022
04540 Gap junction
Cellular Processes; Cell Communication
95 1,366 1 0 16 78 0.037
00500 Starch and sucrose metabolism
Metabolism; Carbohydrate Metabolism
22 237 0 2 4 16 0.042
00604 Glycosphingolipid biosynthesis
ganglio series
Metabolism; Glycan Biosynthesis and Metabolism
20 216 0 0 4 16 0.051
00230 Purine metabolism
Metabolism; Nucleotide Metabolism
106 1,618 1 2 16 87 0.054
04130 SNARE interactions in vesicular transport
Genetic Information Processing; Folding, Sorting and Degradation
19 206 0 4 1 14 0.060
03022 Basal transcription factors
Genetic Information Processing; Transcription
11 105 0 0 4 7 0.062
04910 Insulin signaling pathway
Cellular Processes; Endocrine System
61 889 2 6 9 44 0.071
04350 TGF-beta signaling pathway
Environmental Information Processing; Signal Transduction
43 586 0 1 9 33 0.077
04330 Notch signaling pathway
Environmental Information Processing; Signal Transduction
25 321 0 0 4 21 0.087
04614 Renin-angiotensin system
Cellular Processes; Endocrine System
8 78 0 0 1 7 0.092
KEGG ID, Kyoto Encyclopedia of Genes and Genomes pathway identifier (hsa*); P, P-value of permutation test; SNP, single nucleotide polymorphism
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of looking at ER-negative breast cancer separately as a
unique breast cancer phenotype.
Overall, no significant signal peak was identified in
t h i ss t u d y( F i g u r e s4 ,5 ,6 ,7 ,8 ) .O n l yo n eS N P
(rs361147) was found to achieve genome-wide signifi-
cance after correction for multiple testing in the single
marker analysis. However, the other loci exhibiting
strong associations were interesting for reasons of biolo-
gical significance, and were considered to merit further
research. The associated region on 9q31.1 tagged by
rs7039994 contains two known genes, TEX10 (testis
expressed sequence 10) and INVS (inversin). No func-
tion has been ascribed to TEX10. INVS is reported to
function as a molecular switch between different Wnt
signalling pathways [49] and is also pivotal in the estab-
lishment of the left-right axis. The RHOBTB3 gene, har-
bouring SNP rs3777218, was identified as a putative
breast cancer anti-estrogen resistance gene [50].
However, none of these single markers most strongly
associated with ER-negative breast cancer could be
replicated in a larger, independent sample made up of
two independent studies (Table 1)
To maximize the information obtained from the
GWAS scan, we conducted a permutation-based path-
w a ya n a l y s i su s i n gt h eK E G Gd a t a b a s et oc a p t u r et h e
joint actions of multiple SNPs with modest effects. In
the analysis using default SRT pathway definition files
comprising within-transcript SNPs, metabolic pathways
involving pentose and glucuronate interconversions
(hsa00040) (P =0 . 0 2 2 )a sw e l la ss t a r c ha n ds u c r o s e
metabolism (hsa00500) (P = 0.042) were found to be
nominally significantly related to the risk of developing
ER-negative breast cancer (Table 2). Estrogen-induced
breast cancer cell proliferation is often accompanied by
an increase in intracellular metabolic activity, resulting
in a higher growth rate. The pentose phosphate path-
way, which works in tight conjunction with the pentose
Table 3 Top ranking pathways of genome-wide pathway analysis using regulatory SNPs
P-value distribution of SNPs
Pathway name (KEGG ID)
Class
SRT P P < 0.01 0.01 ≤ P < 0.05 0.05 ≤ P < 0.1 N P of most significant SNP in pathway
Glioma (hsa05214)
Cancers
0.0394 1 5 4 26 0.0028
Long-term potentiation (hsa04720)
Nervous System
0.0394 0 3 2 16 0.0314
Non-small cell lung cancer (hsa05223)
Cancers
0.0394 1 5 3 24 0.0028
Pancreatic cancer (hsa05212)
Cancers
0.0413 2 5 3 33 0.0028
Prostate cancer (hsa05215)
Cancers
0.0488 3 3 6 32 0.0003
Focal adhesion (hsa04510)
Cell Communication
0.0525 1 7 9 71 0.0028
Chemokine signaling pathway (hsa04062)
Immune System
0.0582 1 8 7 72 0.0080
Pathways in cancer (hsa05200)
Cancers
0.0582 2 12 15 151 0.0028
Melanogenesis (hsa04916)
Endocrine System
0.0657 2 2 2 26 0.0003
B cell receptor signaling pathway (hsa04662)
Immune System
0.0713 0 5 3 29 0.0314
GnRH signaling pathway (hsa04912)
Endocrine System
0.0732 0 6 6 46 0.0115
Fc epsilon RI signaling pathway (hsa04664)
Immune System
0.0769 0 6 6 33 0.0314
VEGF signaling pathway (hsa04370)
Signal Transduction
0.0769 0 3 0 17 0.0115
ErbB signaling pathway (hsa04012)
Signal Transduction
0.0788 0 5 5 25 0.0314
Acute myeloid leukemia (hsa05221)
Cancers
0.0957 1 3 3 25 0.0028
Gap junction (hsa04540)
Cell Communication
0.0976 0 5 3 42 0.0314
KEGG ID, Kyoto Encyclopedia of Genes and Genomes pathway identifier; P, P-value of association test in the genome-wide study; SNP, single nucleotide
polymorphism; SRT P, P-value of permutation test for pathway tested
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Page 11 of 17and glucuronate interconversions and starch and
sucrose metabolism pathways, has recently been sug-
gested to be essential for estrogen-dependent cell prolif-
eration [51]. Several pathways that were found to be
marginally significant (P < 0.1) have been suggested to
have potential roles in ER-negative breast cancer,
namely, the TGF-beta signalling pathway [52], the
renin-angiotensin system [53], and the Notch signalling
pathway [54]. In addition, the insulin signalling pathway
has been the focus of targeted therapy for breast cancer
[55], and the purine metabolism pathway is also closely
related to the pentose phosphate pathway described
earlier.
Nevertheless, there is neither a precise biological defi-
nition of a pathway, nor a “standard” method to map
SNPs to genes, and then genes to pathways. Pathway
analyses of GWAS of common diseases have mostly
based SNP-to-gene mappings on the chromosomal posi-
tion of the SNP, whether it occurs within transcript of a
certain gene [19,56]. However, it may be more meaning-
ful to map SNPs that are associated with the expression
of a gene to the gene. To elucidate pathways with more
biological relevance, we further conducted pathway ana-
lysis based on a subset of SNPs with known regulatory
functions. Recent studies have observed that whereas
stronger effects overlap between different tissues, weak
effects on gene regulation are tissue-specific [57,58].
Since we utilized data on gene regulation from lympho-
blasts, we decided to restrict our dataset to only genes
regulated on a genome-wide significant level (LOD >6).
This minimized the bias of tissue-specific gene regula-
tion, but at the same time, limited us to only a fraction
of all possible SNPs genotyped within our GWAS, thus
reducing the power of the analysis.
In spite of the limitations, four of the five significantly
associated pathways (P < 0.05) in our analysis were
found to be annotated as cancer pathways in KEGG
(glioma (hsa05214), non-small cell lung cancer
(hsa05223), pancreatic cancer (hsa05212), and prostate
cancer (hsa05215) (Table 3)), hence confirming the
validity of the choice of this subset of regulatory SNPs
in pathway definition. In addition, a global test of the
Figure 9 Distribution of P-values of regulatory SNPs within KEGG cancer pathways (pathway identifiers beginning with hsa052*).
*Global P-values of cancer-related regulatory SNPs with P < 0.05 in the genome-wide association analysis using the admixture maximum
likelihood test (5,000 permutations) are 0.0028 (unadjusted), and 0.052 (with adjustments made to correct for population stratification).
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effect to be approaching statistical significance (Pa =0 . 0 5
= 0.052). Due to the large number of markers evaluated
in a genome-wide scan, signals with small effects and
modestly significant P-values are likely to be dismissed
after the correction of multiple testing. The implementa-
tion of a pathway analysis thus serves as a complemen-
tation between a hypothesis-driven (prior knowledge of
biological pathways) and a hypothesis-free (genome-
wide scan) approach to highlight certain markers, such
as those found in the cancer pathways, worthy of further
study that would not have been examined otherwise.
The lack of a concordance between the results of path-
way analyses using two different SNP-to-gene mapping
approaches emphasizes the need to put in more
consideration in choosing appropriate pathway defini-
tions. An excess of small P- v a l u e sf o u n df o rS N P sa s s o -
ciated with gene expression involved in cancer-related
pathways suggests that the SNP-gene mapping via asso-
ciation with gene expression approach is superior to the
SNP-gene mapping by location within a transcript
approach, and should be explored in greater detail.
Limitations of this study include an overall lack of sta-
tistical power, especially for the single marker analysis,
and the existence of further heterogeneity among ER-
negative tumours. Although genome-wide pathway-
based analysis is an interesting approach, a main limita-
tion is that the associations observed in this study are
only nominally significant, and would not be significant
after correction for multiple testing. However, as many
Figure 10 Proportion of shared polygenic component between breast cancer estrogen receptor subtypes. Proportion of shared
polygenic component between ER-positive and ER-negative target samples, with respect to their corresponding ER-positive training samples. Pt
denotes P-value cut-off in training sample. a) Test for association between polygenic score and disease status (ER-positive/ER-negative) in the
Swedish data, when all SNPs with P < 0.5 in the Finnish training set were considered. b) Test for association between polygenic score and
disease status (ER-positive/ER-negative) in the Finnish data, when all SNPs with P < 0.5 in the Swedish training set were considered. c)
Significance test for difference in scores (Finnish ER-positive breast cancers derived) between Swedish ER-negative and ER-positive breast cancers,
adjusted for number of non-missing genotypes. Significance codes: ‘- ‘ 0.1 <P < 1 (that is, not significant). d) Significance test for difference in
scores (Swedish ER-positive breast cancers derived) between Finnish ER-negative and ER-positive breast cancers, adjusted for number of non-
missing genotypes. Significance codes: ‘*’ 0.01 <P < 0.05.
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the stringent significance thresholds of traditional multi-
ple testing correction methods are potentially over-con-
servative. There is also indirect evidence that
corroborates our pathway findings. Gene expression stu-
dies have found pathways related to the renin-angioten-
sin system and focal adhesion to be significantly
associated with prognosis of breast cancer [59]. Others
have also reported pathways highlighted in our study,
which are involved in pentose and glucuronate intercon-
versions, gap junction, TGF-beta signalling, rennin-
angiotensin system, B cell receptor signalling, Fc epsilon
RI signalling, VEGF signalling, ErbB signalling, and focal
adhesion, to be significantly associated with the breast
cancer phenotype [59,60]. Although replication of the
pathway results in independent studies would be needed
to confirm the associations, the substantial additional
sample collection and genotyping required are beyond
the scope of this publication.
Although breast cancer has been classified into ER-
positive and ER-negative breast cancers, and these two
breast cancer subtypes have been documented to show
different gene expression patterns, GWAS scans on
breast cancer have always been performed on either
overall breast cancer (ER-positive, ER-negative and
unknown) or ER-positive breast cancer specific risks. In
this study, we found evidence to suggest that ER-nega-
tive breast cancers only share a fraction of the polygenic
component of the disease with ER-positive breast can-
cers, implying that ER-negative breast cancer should be
examined as a distinct breast cancer phenotype.
Although the difference between the polygenic compo-
nents of ER-positive and ER-negative breast cancers was
found only to be significant in the Finnish training sam-
ples, we observed similar differences for all seven P-
value thresholds in the Swedish training samples. How-
ever, due to the smaller number of Swedish ER-negative
cases (N = 153, approximately 33% of Finnish ER-nega-
tive cases), we had less power to detect significant het-
erogeneity between the two subtypes in the Swedish
target samples.
Conclusions
Given the clinical importance of the ER-negative pheno-
type and the likelihood that the relative genetic effect
sizes are small, greater sample sizes and further studies
are required to further the knowledge on ER-negative
breast cancers. Identification of factors for a predisposi-
tion to ER-negative tumours opens the way for under-
standing the underlying etiology of the disease, and may
ultimately result in improvements in prevention, early
detection and specific treatment for this tumour sub-
type. We used a novel approach to pathway analysis,
showing that established cancer pathways could be
regulated by common variants associated to ER-negative
breast cancer. We also provided molecular genetic evi-
dence which suggests that ER-negative breast cancer is a
distinct breast cancer subtype that merits independent
analyses. In view of the biological relevance of the path-
ways identified, a genome-wide pathway approach
deserves merit, and has good potential in pointing out
directions for future research for ER-negative breast
cancers.
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